Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis

John M. McLaughlin(Pfizer (United States)), Luis Jódar(Pfizer (United States)), Raúl Istúriz(Pfizer (United States)), David L. Swerdlow(Pfizer (United States)), Qin Jiang(Pfizer (United States)), Heather L. Sings(Pfizer (United States)), Bradford D. Gessner(Pfizer (United States))

Vaccine

September 12, 2019

10.1016/j.vaccine.2019.08.059

Cited by 57

Related Papers

The Global Burden of Cancer 2013

|JAMA Oncology|2015|2.8k

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

|The Lancet|2017|2.4k

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

|The Lancet|2021|1.7k

Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009

|New England Journal of Medicine|2009|1.7k

H1N1 2009 influenza virus infection during pregnancy in the USA

|The Lancet|2009|1.4k